Arizona AG Sues L'Oréal Over Hair Relaxer Cancer Risks

Arizona has become the first state to bring an enforcement action over chemical hair relaxers, with Attorney General Kris Mayes filing suit in Arizona state court against L'Oréal SA and its U.S. subsidiary. The complaint alleges the cosmetics giant concealed evidence that its hair relaxer products can cause cancer in women and sold them without warning consumers of links to uterine and ovarian cancer. According to reporting on the filing, the state is seeking damages and penalties. The action lands directly on top of the federal hair relaxer MDL — MDL-3060 in the Northern District of Illinois — where L'Oréal is already defending thousands of personal injury claims, and it materially changes the posture of this litigation: a sitting attorney general has now put the state's investigative and enforcement weight behind the core concealment theory that MDL plaintiffs have been building for years.

What Arizona filed — the operative development, precisely stated

This is a complaint, not a ruling. Nothing has been decided on the merits, no discovery has been ordered, and no court has weighed in on Arizona's allegations. What matters at this stage is who filed, where, and on what theory.

The filing was made in Arizona state court, with Mayes announcing the action late this week; Reuters reported the suit on September 11. Named as defendants are L'Oréal SA — the French parent, which trades over the counter in the U.S. under the ticker LRLCF — and its U.S. subsidiary. The core allegation, consistent across every outlet covering the filing, is concealment: that L'Oréal hid evidence its hair relaxer products could cause cancer and marketed chemical straighteners without disclosing the risk. Mayes' office has pointed to product chemistry, saying the relaxers contain toxic chemicals that federal agencies classify as "known or probable human carcinogens." Local Arizona coverage quoted the attorney general characterizing the conduct in one word: "Unacceptable."

On remedies, The Guardian reports the state seeks damages and penalties. The available coverage does not yet specify which statutory counts the complaint pleads. State AG actions of this kind are typically brought under a state's consumer protection statute — in Arizona, consumer fraud enforcement is the usual vehicle for AG suits alleging deceptive marketing and failure to disclose — but until the complaint itself circulates, practitioners should treat the precise causes of action, penalty exposure per violation, and any injunctive or restitution components as open items. That distinction matters more than it might appear, because a consumer-protection enforcement case is measured in civil penalties and equitable relief rather than the compensatory and punitive damages that drive personal injury valuation. The two tracks are complementary, not duplicative.

One more point of precision: this is the first action of its kind by any state, according to Seeking Alpha and Devdiscourse. That "first state" status is the real headline for litigation strategists, because first-in-state AG filings in mass torts historically do not stay solitary for long.

How this litigation got here

The private litigation over chemical hair relaxers has been running for several years. Studies linking long-term relaxer use to hormone-sensitive cancers — particularly uterine cancer, with ovarian cancer also alleged across the docket — triggered a wave of individual filings that were consolidated into MDL-3060, In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, in the Northern District of Illinois. The scientific theory centers on endocrine-disrupting chemicals in relaxer formulations: compounds alleged to interfere with hormone function with repeated scalp exposure, often beginning in childhood. The Guardian notes the Arizona action "echoes thousands of similar suits" — a fair shorthand for an MDL census that has grown steadily since consolidation.

The demographic dimension is central to both the private cases and now the state's case. Devdiscourse's coverage notes the products were widely used by African American women — a population to which relaxers were specifically and heavily marketed for decades. Expect the Arizona complaint's marketing allegations to track the MDL's: targeted advertising, safety messaging, and an alleged failure to warn despite internal or available evidence of carcinogenic risk.

L'Oréal is not the only relaxer manufacturer facing claims in the private litigation, but it is widely treated as the defendant with the deepest resources; the financial distress and bankruptcy restructuring elsewhere in the defendant group over recent years has concentrated exposure analysis on L'Oréal specifically. That context explains why Arizona named L'Oréal — and why the market-facing coverage of this filing ran through financial outlets as well as legal ones.

What had been missing until now was any governmental enforcement action. The FDA has moved slowly on formaldehyde-releasing hair products at the regulatory level, and no state had sued. Arizona just closed that gap.

What it changes

A parallel discovery front outside the MDL's control. The most immediate structural consequence is procedural. Arizona filed in state court, which means this case does not fold into MDL-3060. An AG enforcement action is not a personal injury claim subject to federal consolidation; it will proceed on its own track, before an Arizona judge, on an Arizona timetable. For L'Oréal's defense team, that means a second discovery theater — with a state sovereign, not a private plaintiff, issuing the demands. Documents and testimony produced in the Arizona action will be developed by prosecutors with civil investigative powers and a political mandate, and material surfaced there has a way of migrating into MDL bellwether workups. Defense counsel can no longer manage the concealment narrative through a single coordinated proceeding.

Validation of the concealment theory at a sovereign level. MDL plaintiffs have alleged for years that manufacturers knew or should have known about the cancer risk. A state attorney general filing a formal complaint alleging that L'Oréal hid evidence does not prove that theory — but it changes its public and juridical weight. Bellwether juries are drawn from communities that will have seen this coverage. And if additional AGs follow Arizona's lead, the litigation acquires the multi-front architecture familiar from talc, opioids, and other mass torts where state enforcement and private tort claims ran in parallel and reinforced each other's leverage.

Settlement calculus. Global resolution just got more complicated for L'Oréal — in a way that generally favors private claimants. A defendant negotiating an MDL-wide resolution now has to price in state penalty exposure that cannot be released through a private settlement. Historically, that dynamic pushes defendants toward earlier, broader resolution rather than later, because every month of parallel AG litigation generates discovery and headlines that raise the private docket's value. Conversely, it also means any MDL settlement will not buy total peace, which can cut against a single large number. Firms modeling case values should treat the Arizona action as leverage-positive for the MDL but watch whether remedies sought (penalties, injunctive relief, restitution) create friction with the personal injury track.

What it does not change. The MDL's science fight — general causation, expert admissibility, the strength of the epidemiology on uterine and ovarian cancer — proceeds on its own merits. An AG complaint adds no new evidence to that record by itself. L'Oréal's defenses on causation, dose, and alternative etiology remain intact in the federal proceeding, and nothing in the Arizona filing has been tested by any court.

What this means for plaintiff firms

Expect an awareness spike, and expect it to be geographically uneven. A state attorney general suing a household-name cosmetics company generates mainstream coverage that no private filing achieves — this story ran on Reuters, The Guardian, WWD, and every major Phoenix broadcast outlet within a day. Arizona-market awareness among relaxer users will jump sharply in the coming weeks, and national awareness will rise with it. Historically, AG enforcement actions are among the strongest organic demand catalysts in mass torts because they carry governmental credibility that paid media cannot manufacture: a potential claimant who dismissed lawyer advertising hears differently when the state's top prosecutor says the company concealed a cancer risk.

Case acquisition timing favors moving now, before the follow-on wave. If this filing signals a coordinated or copycat multi-state AG strategy — an open question, but the historical pattern in comparable torts — each subsequent state filing will produce its own awareness spike and its own surge of competing acquisition activity. Firms building hair relaxer dockets get better economics riding organic news-driven demand than competing in a saturated paid environment six months from now. Firms weighing entry or expansion in this tort should consult current hair relaxer market data and campaign benchmarks before the follow-on filings compress the window.

Referral and co-counsel dynamics. The Arizona action will surface claimants whose facts vary widely — long-latency uterine cancer cases that belong in the MDL, weaker exposure histories, and Arizona residents whose interest was triggered by local coverage. Firms without MDL infrastructure should have referral relationships in place before volume arrives; firms with leadership positions in MDL-3060 should anticipate inbound referral flow and staff intake review accordingly. Note also that the AG suit seeks state remedies, not individual compensation — nothing about Arizona's case substitutes for an individual claimant's tort claim, which keeps the private filing pipeline fully intact.

Watch the state-court filing pattern. A live AG enforcement case in Arizona may encourage some plaintiff counsel to file individual Arizona state-court cases rather than joining the federal queue, hoping to draft off the AG's discovery and a favorable local environment. Whether that proves viable depends on removal fights and the complaint's specifics — but it is a docket-strategy question worth evaluating for Arizona-resident clients now rather than after the pattern sets.

Open questions

Which statutory counts the complaint pleads, and the per-violation penalty exposure — the coverage so far does not specify.
Whether L'Oréal attempts removal to federal court or seeks any coordination mechanism with MDL-3060.
Whether other state attorneys general follow Arizona — the strongest signal of a talc/opioid-style multi-front litigation.
What internal evidence Arizona's investigation has already gathered, and how quickly it surfaces into the public record and the MDL.
How the MDL court's bellwether schedule interacts with the state case's timeline, and whether AG discovery accelerates the private docket.
Whether Arizona's remedies demand (penalties, injunctive relief) complicates or catalyzes global settlement talks.

Sources

Mass Tort Ad Agency is a plaintiff-side advertising agency, not a law firm. Nothing in this article is legal advice.